Search research articles
Contact Us
Filters
Showing results (591-600 of 652) with videos related to
Page
of 66
Sort By:
Blood
|
July 16, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Jesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, et al.
Blood Cancer Journal
|
April 2, 2025
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
Carlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang, et al.
Blood
|
July 17, 2014
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Meletios A Dimopoulos, Efstathios Kastritis, Roger G Owen, et al.
Haematologica
|
November 12, 2020
A prognostic index predicting survival in transformed Waldenström macroglobulinemia
Eric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Leukemia
|
August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
BMC Cancer
|
June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
Stefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
The New England Journal of Medicine
|
December 13, 2017
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
María-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Haematologica
|
September 2, 2018
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers, Laurent Garderet, K Martin Kortüm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2020
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
Efstathios Kastritis, Xavier Leleu, Bertrand Arnulf, et al.
Leukemia
|
November 26, 2022
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia
Irene Dogliotti, Cristina Jiménez, Marzia Varettoni, et al.
Page
of 66
Search research articles
Search
Showing results (591-600 of 652) with videos related to
Sort By:
Page
of 66
Blood
|
July 16, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Jesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, et al.
Blood Cancer Journal
|
April 2, 2025
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
Carlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang, et al.
Blood
|
July 17, 2014
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Meletios A Dimopoulos, Efstathios Kastritis, Roger G Owen, et al.
Haematologica
|
November 12, 2020
A prognostic index predicting survival in transformed Waldenström macroglobulinemia
Eric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Leukemia
|
August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
BMC Cancer
|
June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
Stefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
The New England Journal of Medicine
|
December 13, 2017
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
María-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Haematologica
|
September 2, 2018
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers, Laurent Garderet, K Martin Kortüm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2020
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
Efstathios Kastritis, Xavier Leleu, Bertrand Arnulf, et al.
Leukemia
|
November 26, 2022
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia
Irene Dogliotti, Cristina Jiménez, Marzia Varettoni, et al.
Page
of 66